HC Wainwright Rates Insmed (INSM) Buy, $220 Price Target

HC Wainwright has reiterated its Buy rating on Insmed with a price target of $220 as of October 12, 2026, a 128.69% upside from the current price.

By TradeTexts Research Desk · Published Oct 16, 2026, 2:17 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated Insmed Incorporated ($INSM) "Buy" with a $220 price target on October 12, 2026.

Since the rating, $INSM is down 2.3% to date (from the $98.56 close on Oct 12, 2026).

INSM Insmed Incorporated

$96.27 -45.65% year to date

Daily close · Oct 16, 2026

Key Points

HC Wainwright maintains a Buy rating on Insmed Incorporated with a price target of $220.00 as of October 12, 2026.
HC Wainwright's $220 price target implies 128.69% upside from Insmed Incorporated's ($INSM) current $96.20 share price.
Recently, Insmed shares traded at $96.20, which is 56.3% below the analyst's target.
Insmed's revenue for the trailing twelve months was approximately $1.14 billion, reflecting a year-over-year growth of 296.1%.

Get $INSM trade alerts by text

We text you when insiders, Congress or big funds trade $INSM. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Insmed Incorporated alert may contain errors. Disclosures

HC Wainwright has reiterated its Buy rating on Insmed Incorporated (NasdaqGS: INSM) with a price target of $220.00 as of October 12, 2026. This follows a recent trading period where shares were priced at $96.20, which is significantly below the target by 56.3%.

Other Institutional Activity in Insmed Incorporated

FMR, LLC holds about 16.1 million shares of Insmed, with a total value of approximately $1.55 billion, after increasing its stake by 2.98 million shares, a 22.7% rise. Meanwhile, BlackRock Inc. trimmed its holdings by 870,623 shares, leaving it with 15.8 million shares valued at about $1.52 billion, reflecting a decrease of 5.2%. JPMorgan Chase & Co. reported a significant reduction of 13.7 million shares, now holding 10.4 million shares worth about $1.0 billion, a drop of 56.8%. Additionally, Vanguard Portfolio Management LLC slightly increased its holdings by 36,301 shares, totaling 10.4 million shares valued at approximately $1.0 billion, with a minor change of 0.3%.

Insmed Incorporated Stock Down 3.0%

Insmed shares are currently trading at $96.20, which is well below the analyst's target of $220.00. This positioning suggests that shares may be undervalued compared to the bullish outlook set by HC Wainwright. The stock's performance is particularly noteworthy considering the high revenue growth rate of 296.1% year-over-year.

12-month forecast

$INSM price target

Insmed Incorporated daily closes and this analyst's $220 target. Not advice.

Recent Earnings

For the trailing twelve months, Insmed reported revenue of approximately $1.14 billion. However, the company has not yet turned a profit, with a net margin of -76.9% and a return on equity of -87.2%. Investors will be looking for improvements in future earnings, with the next earnings report scheduled for October 29, 2026.

Insider Buying and Selling at Insmed Incorporated

Recent insider transactions include Chief Operating Officer Roger Adsett, who sold 239,850 shares at an average price of $133.27 on August 10, 2026, totaling about $31.96 million. Other notable sales include Director Melvin A. Sharoky, who sold 5,000 shares at $127.53, and Director David R. Brennan, who sold 25,000 shares at $124.00. Both transactions occurred before the recent analyst ratings.

Analysts Set New Price Targets

On the same day as HC Wainwright's reiteration, Wolfe Research downgraded Insmed to a Peer Perform rating. Earlier in August and September, other firms like JP Morgan and Roth Capital maintained their ratings, with targets of $175.00 and $198.00 respectively, indicating mixed views among analysts.

About Insmed Incorporated

Insmed Incorporated develops therapies for patients with serious and rare diseases. It is known for its product ARIKAYCE, which treats specific lung infections, and is currently conducting a phase 3 trial for another treatment. The company's focus on niche markets is crucial for its growth strategy, especially as it continues to expand its offerings.

Bottom Line

Investors should keep an eye on Insmed as it approaches its earnings date on October 29, 2026. The company's recent performance and the mixed analyst ratings suggest a volatile outlook. Further updates from analysts will be important as they evaluate the effectiveness of Insmed's therapies and their market impact.